AxoBioFluid® A is an ambient (room temperature) amniotic allograft fluid that is an alternative to the existing cryopreserved AxoBioFluid®. Both products are media conditioned by amniotic mesenchymal stromal cells (MSC), and amniotic epithelial cells (AEC); which contain associated growth factors that are released during cell culture.
AxoBioFluid® A is available for order immediately and will start shipping on October 1st. The product is available in four standard sizes 0.5ml, 1.0ml, 1.5ml, and 2.0ml, as well as custom sizes which may be ordered.
“AxoBioFluid® A meets our customer demand to have an injectable product that can be stored at room temperature, ready for use, and has an extended shelf life. This is another example of our focus on providing significant improvements in patient outcomes, while delivering high value for clinicians,” noted Bob Maguire, founder and CEO of Axolotl Biologix.
About Axolotl Biologix, Inc.
Axolotl Biologix, Inc., is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue medical technologies that are disrupting traditional, more invasive, painful, and expensive treatment protocols. The Phoenix-based
company is rapidly building a portfolio of unique, patented regenerative treatment products to improve patient outcomes with less pain and lower costs. For more information, please visit the company’s website at www.axobio.com.
Media:
pr@axobio.com
Bob Maguire
602-354-3081